Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Baudin

Showing results (231-240 of 241) with videos related to

Pageof 25
Sort By:
Nature Reviews. Endocrinology|May 22, 2021
International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriersLaurence Amar, Karel Pacak, Olivier Steichen, et al.
The New England Journal of Medicine|May 4, 2012
Combination chemotherapy in advanced adrenocortical carcinomaMartin Fassnacht, Massimo Terzolo, Bruno Allolio, et al.
BMC Cancer|April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
The Journal of Clinical Endocrinology and Metabolism|December 15, 2016
DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical CancerAnne Jouinot, Guillaume Assie, Rossella Libe, et al.
The Lancet. Diabetes & Endocrinology|August 24, 2023
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational studyMassimo Terzolo, Martin Fassnacht, Paola Perotti, et al.
Human Molecular Genetics|February 5, 2013
Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort studyJulien Thevenon, Abderrahmane Bourredjem, Laurence Faivre, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Thyroid : Official Journal of the American Thyroid Association|October 16, 2023
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter StudyBin Xu, Kartik Viswanathan, Mahsa S Ahadi, et al.
Neuroendocrinology|October 10, 2018
Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort StudyGuido Rindi, Catherine Klersy, Luca Albarello, et al.
European Journal of Endocrinology|November 9, 2020
ENSAT registry-based randomized clinical trials for adrenocortical carcinomaJoakim Crona, Eric Baudin, Massimo Terzolo, et al.
Pageof 25

Showing results (231-240 of 241) with videos related to

Sort By:
Pageof 25
Nature Reviews. Endocrinology|May 22, 2021
International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriersLaurence Amar, Karel Pacak, Olivier Steichen, et al.
The New England Journal of Medicine|May 4, 2012
Combination chemotherapy in advanced adrenocortical carcinomaMartin Fassnacht, Massimo Terzolo, Bruno Allolio, et al.
BMC Cancer|April 4, 2025
A Randomized clinical trial evaluating the impact on survival and quality of life of <sup>177</sup>Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Jaume Capdevila, Virginia Pubul, Urbano Anido, et al.
The Journal of Clinical Endocrinology and Metabolism|December 15, 2016
DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical CancerAnne Jouinot, Guillaume Assie, Rossella Libe, et al.
The Lancet. Diabetes & Endocrinology|August 24, 2023
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational studyMassimo Terzolo, Martin Fassnacht, Paola Perotti, et al.
Human Molecular Genetics|February 5, 2013
Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort studyJulien Thevenon, Abderrahmane Bourredjem, Laurence Faivre, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Thyroid : Official Journal of the American Thyroid Association|October 16, 2023
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter StudyBin Xu, Kartik Viswanathan, Mahsa S Ahadi, et al.
Neuroendocrinology|October 10, 2018
Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort StudyGuido Rindi, Catherine Klersy, Luca Albarello, et al.
European Journal of Endocrinology|November 9, 2020
ENSAT registry-based randomized clinical trials for adrenocortical carcinomaJoakim Crona, Eric Baudin, Massimo Terzolo, et al.
Pageof 25